Equities

Mendus AB (publ)

Mendus AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)0.45
  • Today's Change-0.024 / -5.06%
  • Shares traded1.94m
  • 1 Year change-58.24%
  • Beta1.1894
Data delayed at least 15 minutes, as of Mar 28 2024 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-101.62m
  • Incorporated2002
  • Employees30.00
  • Location
    Mendus AB (publ)Ostermalmstorg 5STOCKHOLM 111 53SwedenSWE
  • Phone+46 87328400
  • Websitehttps://mendus.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kancera AB0.00-64.89m252.91m3.00---------0.786-0.7860.00--------0.00---54.82---66.21-------7,249.06-------------23.64------
Corline Biomedical AB25.03m-1.81m255.74m13.00--2.74--10.22-0.0841-0.08411.164.340.248--10.921,925,385.00-1.79-5.71-1.92-6.24113.38128.60-7.22-38.46---89.40----6.2874.14-177.67--62.51--
Ultimovacs ASA0.00-186.43m270.15m27.00--0.9815-----5.50-5.500.008.120.00----0.00-44.08-28.80-50.02-31.12------------0.0131-------12.78---45.35--
Intervacc AB8.02m-102.85m280.22m15.00--1.18--34.96-1.47-1.470.11673.140.03063.081.72---39.21-17.62-42.12-18.77-628.60-243.59-1,283.24-626.904.38--0.0006---17.23-25.79-60.31---38.72--
Lumito AB (publ)0.00-25.80m280.76m15.00--2.72-----0.125-0.1250.000.49970.00----0.00-19.98-20.77-22.14-22.38--------1.42--0.0884------4.56------
SynAct Pharma AB0.00-215.81m307.33m5.00--1.74-----6.54-6.540.004.950.00----0.00-116.46-125.17-130.53-151.70------------0.0036-------117.54------
Medivir AB7.60m-89.40m307.87m10.00--1.31--40.51-1.08-1.080.08922.100.0291--1.57760,000.00-34.25-28.91-41.07-34.77-806.58-467.79-1,176.32-676.29----0.0493--72.41-20.45-0.6027---46.49--
Ascelia Pharma AB0.00-109.29m310.91m24.00--4.32-----3.20-3.200.002.130.00-------71.51---85.53--------------0.0141------16.72------
Herantis Pharma Oyj0.00-63.12m326.94m-----------0.3219-0.32190.00-0.10970.00-------72.74-80.46-107.82-104.37-----------26.441.69------103.00------
Magle Chemoswed Holding AB170.44m12.17m347.76m--28.582.2013.762.041.131.1315.7814.650.64120.495510.28--4.582.516.003.5290.3185.677.143.920.6716.160.2760--17.009.9733.07---6.34--
Lifecare AS17.04m-24.50m378.66m----8.15--22.22-0.1995-0.19950.13960.34960.3753--27.43---53.96-41.60-60.93-47.04-----143.78-147.96---67.840.155--1,284.20109.30-10.08------
Mendus AB (publ)0.00-101.62m388.42m30.00--0.5512-----0.2566-0.25660.000.81650.00----0.00-14.77-18.84-15.78-20.21-------28,474.53----0.0325---100.00--26.78------
INIFY Laboratories AB1.19m-53.31m414.32m----4.87--347.42-1.20-1.200.02681.91----------------71.50---4,470.08---------------20.76------
Nightingale Health Oyj42.18m-208.44m470.96m81.00--0.6949--11.17-0.2979-0.29790.06031.500.03441.603.8744,560.98-17.02-14.20-18.12-15.6975.8183.57-494.25-408.5014.15--0.0378--80.8019.05-12.38------
Initiator Pharma A/S0.00-35.39m483.64m3.00--27.77-----0.6511-0.65110.000.32910.00----0.00-58.55-65.10-62.50-70.59------------0.5804------40.52------
Bergenbio ASA348.75k-187.58m513.87m18.00--4.09--1,473.46-0.2647-0.26470.00020.04740.0021-------111.66-66.15-176.09-78.74-----53,785.59-11,419.44----0.00---9.00-31.4336.98------
Data as of Mar 28 2024. Currency figures normalised to Mendus AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

5.08%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Dec 202221.25m3.15%
SEB Investment Management ABas of 29 Feb 20246.62m0.98%
Handelsbanken Fonder ABas of 29 Feb 20245.13m0.76%
FCG Fonder ABas of 31 Dec 2022677.88k0.10%
WBS H�nicke Verm�gensverwaltung GmbHas of 31 Dec 2023538.80k0.08%
Storebrand Asset Management ASas of 31 Jan 202433.33k0.01%
Skandia Investment Management ABas of 31 Jan 202432.42k0.01%
Case Kapitalf�rvaltning ABas of 30 Nov 202210.86k0.00%
More ▼
Data from 31 Dec 2022 - 31 Jan 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.